Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- 3-Drug H. pylori Eradication Therapy Receives Additional Indication for H. pylori Gastritis
February 25, 2013
- Zeria to Launch Hypophosphatemia Treatment Phosribbon Combination Granules on March 4
February 25, 2013
- MTPC Calls for Proper Use of Telavic Following Reports of Serious Infections
February 25, 2013
- LEO Pharma of Denmark to Fully Enter Psoriasis Market in Japan in 2014
February 22, 2013
- Lotriga, Equa, Aimix Most Promoted Products in GP, HP Markets in January: Rep Track Survey
February 22, 2013
- Astellas Files for Additional Indication for Dormicum Based on Data from Public Domain
February 22, 2013
- Shionogi Settles Lawsuit over Royalties Payment with US Firm InterMune
February 22, 2013
- Shire Appoints Steve Engen as Representative Director of Japanese Subsidiary
February 22, 2013
- Actelion Receives Approval for Generic Version of Flolan
February 22, 2013
- Chugai Sues 4 Companies Including Iwaki Seiyaku for Patent Infringement Related to Oxarol Ointment
February 21, 2013
- HIV Treatment Dolutegravir Gets FDA Priority Review: ViiV Healthcare
February 21, 2013
- Radium-223 Granted Priority Review Status by US FDA: Bayer HealthCare
February 19, 2013
- DSP Targets Sales of 450 Billion Yen in FY2017 by Making Latuda Blockbuster
February 19, 2013
- Blopress Retakes Top Spot in Domestic Ethical Drug Market in 2012: IMS Japan
February 19, 2013
- Kowa Says Listing Application for Livalo Generic “Won’t Be Filed”; Possibility Nixed for 1st AG in Japan
February 18, 2013
- No Statistical Significance Shown in OS between Tivozanib and Sorafenib in PIII Study: Astellas
February 18, 2013
- Nihon Medi-Physics to Establish New Manufacturing Base for PET Diagnostics in Fujioka City, Gunma Prefecture
February 18, 2013
- Small and Medium Sized Pharmacies Jointly Buys Generics Directly from Manufacturers
February 15, 2013
- Takeda Subsidiary Suspends Operations for 12 Days Due to Alinamin-F5 Injection Recalls
February 15, 2013
- Daiichi Sankyo to Launch New Firm for Duchenne Muscular Dystrophy Therapy Jointly with Govt-Backed Fund
February 15, 2013
ページ
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…